Italy Pharma & Healthcare News: New CSO for Angelini; Big Digital Health Investments; Menarini/Karyopharm Tie-Up Details


The latest news from the Italian healthcare and life sciences industries, including the final piece in Angelini’s updated leadership team; the country’s digital health investment timetable; and the details of Menarini’s Europe commercialisation deal for Karyopharm’s NEXPOVIO in Europe.


Angelini Pharma Appoints Rafal Kaminski as New Chief Scientific Officer (Business Wire)

Angelini Pharma, an international pharmaceutical company which is part of the privately-owned Angelini Industries, has appointed Rafal Kaminski as its new Chief Scientific Officer. Rafal Kaminski has broad international experience in drug discovery and innovation and will lead Angelini Pharma’s research and development (R&D) strategy. He will commence his role in January 2022.

“I am excited for Rafal’s appointment which completes our leadership team. He will be instrumental in enabling us to develop a solid leadership in the field of brain health and rare diseases” commented Pierluigi Antonelli, Chief Executive Officer Angelini Pharma. “Rafal brings a significant wealth of experience having led R&D from discovery to clinical development of small innovative molecules. He will be responsible for driving our current and future pipeline development strategy, including our distinctive research and innovation model”.


Italian Ministers Announce Timetable for Investment in Digital Health (The National Law Review)

On January 8, 2022, Minister of Health Roberto Speranza and Minister for Technological Innovation and Digital Transition Vittorio Colao, in an article published in the Italian press, made a number of announcements about the timing of the Italian government’s intended investment in digital health. This investment forms part of the Italian Recovery and Resilience Plan (RRP).

On July 13, 2021, the European Council approved the final version of the RRP. The RRP is part of the EU Next Generation program (NGEU), namely the €750 billion package of which €222 billion has been allocated to Italy.


Menarini Group To Commercialize Karyopharm’s NEXPOVIO In Europe – Quick Facts (Nasdaq)

Karyopharm Therapeutics Inc. (KPTI) and the Menarini Group announced an exclusive licensing agreement, under which Menarini will commercialize NEXPOVIO, Karyopharm’s oral Selective Inhibitor of Nuclear Export compound, in Europe and other key global territories. Menarini received exclusive rights to commercialize NEXPOVIO for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries.

Karyopharm will receive an upfront payment of $75 million in 2021 and is eligible to receive up to an additional $202.5 million in future milestones, plus tiered double-digit royalties on net sales of NEXPOVIO.

Read PharmaBoardroom’s 2020 interview with Karyopharm Founder & CEO Michael G. Kauffman here


Alfasigma interconnects machines with Schneider Electric’s Data Wizard solution (Automazione Plus)

Alfasigma, a pharmaceutical company with entirely Italian capital born from the merger between the Alfa Wasserman and Sigma-Tau groups, has chosen Schneider Electric’s Data Wizard solution to start a process of introducing digital technologies in its historic production site in Pomezia, active since 1960s as a Sigma-Tau plant.


Half of Italy’s households go without healthcare (Euractiv)

Over half the families in Italy (50.2%) went without health care services, partially due to COVID-19, between spring 2020 and November 2021, the Cerved Group’s 2022 report on Italian Household Welfare presented Wednesday in Rome has found. At the same time, household spending on healthcare, eldercare, and education went up €5,000, corresponding to 17% of an average household’s net income.

In total, spending went up to €136 billion during that period, of which €38.8 billion was for healthcare, €29.4 billion for elderly care, and €12.4 billion for education.

Related Content

Latest Report